Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

被引：0
|
作者：
William V. Padula
Sonal Parasrampuria
Mariana P. Socal
Rena M. Conti
Gerard F. Anderson
机构：
[1] University of Southern California,Department of Pharmaceutical and Health Economics, School of Pharmacy, USC Schaeffer Center
[2] University of Southern California,Leonard D. Schaeffer Center for Health Policy and Economics
[3] Johns Hopkins Bloomberg School of Public Health,Department of Health Policy and Management
[4] Boston University Questrom School of Business,Institute for Health System Innovation and Policy
来源：
PharmacoEconomics | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1115 / 1121
页数：6
相关论文
共 50 条
  • [1] Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
    Richard Manning
    PharmacoEconomics, 2020, 38 : 1373 - 1374
  • [2] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US
    Padula, William V.
    Parasrampuria, Sonal
    Socal, Mariana P.
    Conti, Rena M.
    Anderson, Gerard F.
    PHARMACOECONOMICS, 2020, 38 (10) : 1115 - 1121
  • [3] Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US"
    Manning, Richard
    PHARMACOECONOMICS, 2020, 38 (12) : 1373 - 1374
  • [4] Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
    William V. Padula
    Sonal Parasrampuria
    Mariana P. Socal
    Rena M. Conti
    Gerard F. Anderson
    PharmacoEconomics, 2020, 38 : 1375 - 1376
  • [5] Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US"
    Padula, William V.
    Parasrampuria, Sonal
    Socal, Mariana P.
    Conti, Rena M.
    Anderson, Gerard F.
    PHARMACOECONOMICS, 2020, 38 (12) : 1375 - 1376
  • [6] ECONOMIC IMPACT OF THE END OF THE MARKET EXCLUSIVITY FOR ORPHAN DRUGS
    Kandel, M.
    Degrassat-Theas, A.
    de Curzon, Parent O.
    Sinegre, M.
    Paubel, P.
    VALUE IN HEALTH, 2015, 18 (07) : A678 - A678
  • [7] Impact of orphan drugs on Latvian budget
    Konstantins Logviss
    Dainis Krievins
    Santa Purvina
    Orphanet Journal of Rare Diseases, 11
  • [8] Impact of orphan drugs on Latvian budget
    Logviss, Konstantins
    Krievins, Dainis
    Purvina, Santa
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [9] The Budget Impact of Orphan Drugs in the US: A 20072013 MIDAS Sales Data Analysis
    Divino, Victoria
    Dekoven, Mitch
    Wang, Weiying
    Kleinrock, Michael
    Harvey, R. Donald
    Wade, Rolin L.
    Kaura, Satyin
    BLOOD, 2014, 124 (21)
  • [10] Societal Impact Of Extending Market Exclusivity For Conventional Drugs
    Musselwhite, Laura
    Collingsworth, Bryan
    HEALTH AFFAIRS, 2011, 30 (04)
12345